SciBase closes first DermoScan integration sale in Germany

SciBase has received the first order from a customer as a result of their co-operation with the German medical technology company DermoScan. The order comes from a clinic in Munich that is a user of a DermoScan digital dermoscopy system and who has now chosen to add Nevisense to its diagnostic process. 

Earlier this year SciBase and DermoScan signed an agreement to integrate and share patient clinical information and results from Nevisense with DermoScan’s dermoscopy system DermoGenius Ultra. DermoScan is the first digital dermoscopy company to include EIS as a standard parameter. DermoGenius Ultra is today used by over 400 clinics in Germany. 

- Integration between all the systems I use is very important for us in our clinic and so the integration between Nevisense and DermoGenius Ultra was essential. Integration enables us to include Nevisense as a natural part of our workflow.  We are very pleased to be able to offer our patients the integrated solution, says Dr. Thomas and Dr. Ameli Weber at the clinic Hautarzt Weber in Munich. 

Nevisense will be a valuable add-on to the visual assessment provided by DermoScan’s digital dermoscopy system. It will be easier to include Nevisense and the EIS-measurement into the clinic’s workflow, which will improve clinic efficiency.  The integration also makes it possible, through DermoGenius, to connect Nevisense with almost all of EMR (Electronic medical record) systems available in Germany.

- We have been in discussion with this clinic over a period of time and what was decisive was the integration of Nevisense with DermoGenius Ultra, which they already use. We see this first order as a signal that we now have the possibility to reach a new customer group - which is a part of our more ambitious growth strategy, says Simon Grant CEO of SciBase.  

For more information, please contact:
Simon Grant, CEO SciBase
Phone: +46 72 887 43 99
Email: simon.grant@scibase.com  

About SciBase and Nevisense
SciBase AB is a Swedish medical technology company, headquartered in Stockholm that has developed a unique point-of-care device for the accurate detection of malignant melanoma. Its product, Nevisense, helps doctors to detect malignant melanoma, the most dangerous type of skin cancer. SciBase was founded by Stig Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia, and now also a FDA clearance in the United States. Nevisense is based on a method called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies. SciBase is listed on Nasdaq First North (“SCIB”). Avanza is the certified advisor. Further information is available on www.scibase.com.